In one paragraphArticle in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors.
Eric J BarnettPsychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab), Department of Psychiatry and Behavioral Sciences, Norton College of Medicine at SUNY Upstate Medical University, Syracuse, New York, USA.ORCID 0000-0003-2493-2251 Jonathan L HessPsychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab), Department of Psychiatry and Behavioral Sciences, Norton College of Medicine at SUNY Upstate Medical University, Syracuse, New York, USA.ORCID 0000-0001-8406-632X Jiahui HouBiomedical Informatics, School of Medicine, University of Pittsburgh.
Valentina Escott-PriceDementia Research Institute, School of Medicine, Cardiff University, Cardiff, UK.ORCID 0000-0003-1784-5483 Christine Fennema-NotestineDepartment of Psychiatry, University of California San Diego, La Jolla, California, USA.ORCID 0000-0002-6527-6361 William KremenDepartment of Psychiatry, University of California San Diego, La Jolla, California, USA.ORCID 0000-0002-8629-5609 Shu-Ju LinDepartment of Psychiatry, University of California San Diego, La Jolla, California, USA.
Chunling ZhangDepartment of Neuroscience and Physiology, Norton College of Medicine at SUNY Upstate Medical University, Syracuse, New York, USA.ORCID 0000-0003-2752-1028 Chris GaiteriDepartment of Psychiatry and Behavioral Sciences, Norton College of Medicine at SUNY Upstate Medical University, Syracuse, New York, USA.ORCID 0000-0001-7838-8664 Jeremy ElmanDepartment of Psychiatry, University of California San Diego, La Jolla, California, USA.ORCID 0000-0002-5840-1769 Peter HolmansDivision of Psychological Medicine and Clinical Neurology and Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, UK.ORCID 0000-0003-0870-9412 Stephen V FaraoneDepartment of Neuroscience and Physiology, Norton College of Medicine at SUNY Upstate Medical University, Syracuse, New York, USA.ORCID 0000-0002-9217-3982 Stephen J GlattPsychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab), Department of Psychiatry and Behavioral Sciences, Norton College of Medicine at SUNY Upstate Medical University, Syracuse, New York, USA.ORCID 0000-0002-0360-7567 Funding
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jessica Lynette Montoya · 2001 to 2026
$50.4MThe VETSA Longitudinal Twin Study of Cognition and Aging (VETSA 4)R01AG050595 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ELMAN, JEREMY A, FRANZ, CAROL ELAINE · 2015 to 2024
$28.0MUrban Air Pollution and Pathological Brain Aging: A Nationwide Twin Study in MenP01AG055367 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MACK, WILLIAM J · 2018 to 2022
$11.5MDATA COORDINATING CENTER TO PROVIDE SERVICES TO WORK COLLABORATIVELY WITH THE NATIONAL NEUROHIV TISSUE CONSORTIUM CLINICAL SITES TO PROVIDE MANAGEMENT AND DATABASE CAPABILITIES, SCIENTIFIC EXPERTISE, 75N95023C00013 · NIDA · THE EMMES COMPANY, LLC · PI SHERMAN, SETH · 2023 to 2025
$11.2MCHARTER Plus: A resource for cutting-edge research on neurological function and mental health in people with HIV and substance use disorders across the lifespanR24MH129166 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RONALD J. ELLIS, Scott L Letendre · 2022 to 2026
$9.9MOligodendrocyte damage and dysfunction in HIV associated neurocognitive disorderR01MH098742 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI JUDITH B GRINSPAN, Kelly L Jordan-Sciutto · 2012 to 2026
$9.0MThe VETSA Longitudinal MRI Twin Study of Aging (VETSA MRI 4)R01AG076838 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ANDERS M DALE, Jeremy A Elman · 2022 to 2026
$8.7MSLE Treatment with N-acetylcysteineU01AR076092 · NIAMS · UPSTATE MEDICAL UNIVERSITY · PI Michael P McDermott, Andras Perl · 2020 to 2026
$7.9MIdentifying therapeutic targets that confer synaptic resilience to Alzheimer's diseaseR01AG061800 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Christopher A. Gaiteri, Jeremy H. Herskowitz · 2018 to 2026
$6.9MRole of myosin 1e in podocyte biology and renal filtrationR01DK083345 · NIDDK · UPSTATE MEDICAL UNIVERSITY · PI Mira Krendel · 2011 to 2026
$6.8MPerson-centered diagnostics and prediction for child dysregulatory psychopathology using novel phenotypesU01MH135970 · NIMH · OREGON HEALTH & SCIENCE UNIVERSITY · PI KARALUNAS, SARAH LYN, NAGEL, BONNIE J. · 2024 to 2025
$6.5MIdentifying the origins of resilience through human single cell molecular networks, then testing them in diverse, resilient, human IPS linesR01AG061798 · NIA · UPSTATE MEDICAL UNIVERSITY · PI GAITERI, CHRISTOPHER A. · 2018 to 2023
$5.5MNIAMS NIH HHS U01 AR076092NIA NIH HHS K01 AG063805NIA NIH HHS P01 AG055367NIA NIH HHS R01 AG050595NIA NIH HHS R01 AG060470NIA NIH HHS R01 AG061798NIA NIH HHS R01 AG061800NIA NIH HHS R01 AG064955NIA NIH HHS R01 AG076838NIA NIH HHS U01 AG079847NIDA NIH HHS 75N95023C00013NIDA NIH HHS R01 DA047879NIDA NIH HHS R01 DA047906NIDDK NIH HHS R01 DK083345NIMH NIH HHS P30 MH062512NIMH NIH HHS R01 MH098742NIMH NIH HHS R01 MH116037NIMH NIH HHS R01 MH125720NIMH NIH HHS R01 MH126459NIMH NIH HHS R01 MH130899NIMH NIH HHS R01 MH131685NIMH NIH HHS R21 MH126494NIMH NIH HHS R24 MH129166NIMH NIH HHS U01 MH135970NINDS NIH HHS R01 NS128535
6 · The paper itselfAbstract
Background: Genetic risk factors for psychiatric and neurodegenerative disorders are well documented. However, some individuals with high genetic risk remain unaffected, and the mechanisms underlying such resilience remain poorly understood. The presence of protective resilience factors that mitigate risk could help explain the disconnect between predicted risk and reality, particularly for brain disorders, where genetic contributions are substantial but incompletely understood. Identifying and studying resilience factors could improve our understanding of pathology, enhance risk prediction, and inform preventive measures or treatment strategies. However, such efforts are complicated by the difficulty of identifying resilience that is separable from low risk. Methods: We developed a novel adversarial multi-task neural network model to detect genetic resilience markers. The model learns to separate high-risk unaffected individuals from affected individuals at similar risk while "unlearning" patterns found in low-risk groups using adversarial learning. In simulated and existing Alzheimer's disease (AD) datasets, we identified markers of resilience with a feature-importance-based approach that prioritized specificity, generated resilience scores, and analyzed associations with polygenic risk scores (PRS). Results: In simulations, our model had high specificity and moderate sensitivity in identifying resilience markers, outperforming traditional approaches. Applied to AD data, the model generated genetic resilience scores protective against AD and independent of PRS. We identified five resilience-associated SNPs, including known AD-associated variants, underscoring their potential involvement in risk/resilience interactions. Conclusions: Our methods of modeling and evaluation of feature-importance successfully identified resilience markers that were obscured in previous work. The high specificity of our model provides high confidence that these markers reflect resilience and not simply low risk. Our findings support the utility of resilience scores in modifying risk predictions, particularly for high-risk groups. Expanding this method could aid in understanding resilience mechanisms, potentially improving diagnosis, prevention, and treatment strategies for AD and other complex brain disorders.
Indexed as
Adversarial LearningAlzheimer’s DiseaseGenetic ResilienceMachine LearningPolygenic RiskSimulation
Identifiers
PMID40061341
PMCPMC11888503
What Socratic holds
Textmetadata
Read underepoch 390